Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
52 Results for "
Plasma kallikrein
" in MedChemExpress (MCE) Product Catalog:
Products (52)
52 Results for "Plasma kallikrein" in MCE Product Catalog:
6
Target:
Research Areas:
Avoralstat (BCX4161), a potent and orally active plasma kallikrein (PKK) inhibitor, is used for hereditary angioedema research .
2
Target:
Research Areas:
1
Target:
Research Areas:
Sebetralstat (KVD900) is an orally active and selective plasma kallikrein inhibitor, with an IC50 of 6.0 nM and a Ki of 3.0 nM against the human target. Sebetralstat binds to the active site of plasma kallikrein, inducing a conformational flip of Trp215 to form a U-shaped conformation; its P1 group interacts with the S1 pocket through hydrophobic interactions and displacement of high-energy water molecules, independent of the Asp189 ionic bond. Sebetralstat inhibits plasma kallikrein-kinin system activation in whole plasma, rapidly relieves laryngeal and abdominal attack symptoms of hereditary angioedema (HAE-C1INH), and reduces attack severity. Sebetralstat can be used in research related to hereditary angioedema (HAE) .
1
1 Cited Publications
Cat. No.: HY-P4245
CAS No.: 88546-74-1
Target:
Research Areas:
1
Target:
Research Areas:
Berotralstat (BCX7353) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema .
1
1 Cited Publications
Synonyms: BCX7353 dihydrochloride
Target:
Research Areas:
Berotralstat dihydrochloride (BCX7353 dihydrochloride) is an orally active plasma kallikrein inhibitor. Berotralstat can reduce brain edema and is being studied for glioblastoma and hereditary angioedema .
Target:
Research Areas:
Plasma kallikrein-IN-4 (Example 153) is a plasma kallikrein inhibitor with an IC50 of 0.016 μM against human plasma kallikrein .
Cat. No.: HY-P99110
CAS No.: 1426055-14-2
Synonyms: SHP643; DX-2930; X124-G01
Target:
Research Areas:
Target:
Research Areas:
BMS-962212 is a factor XIa (FXIa) inhibitor with a Ki of 0.7 nM against human FXIa and a Ki of 3 nM against rabbit FXIa. BMS-962212 blocks thrombosis while preserving normal hemostatic function. BMS-962212 is applicable to thrombosis-related research .
Target:
Research Areas:
Kallikrein, Porcine pancreas (kininogenase) is capable of forming the kallikrenase kalinin system (KKS) in plasma and tissues, producing bradykinin and kalin peptides, respectively .
Research Areas:
MDI-2268 is an inhibitor of plasma kallikrein inhibitor 1 (PAI-1). MDI-2268 has good antithrombotic properties and regulates blood coagulation and fibrinolysis process by enhancing fibrinolysis. MDI-2268 can be used in research areas such as deep vein thrombosis .
Target:
Research Areas:
PKSI-527 is a new, highly selective plasma kallikrein inhibitor. PKSI-527 can suppress collagen-induced arthritis (CIA) by modifying the kallikrein-kinin system .
Cat. No.: HY-122142A
CAS No.: 127428-47-1
Synonyms: S-2366 (hydrochloride)
Target:
Research Areas:
Pyr-Pro-Arg-pNA (S-2366) hydrochloride is a chromogenic peptidyl substrate, and a noncompetitive inhibitor that occupies the active sites of FXIa and FXIa-LC to block factor IX activation. Pyr-Pro-Arg-pNA hydrochloride functions as a hydrolyzable substrate for FXIa’s catalytic domain, human APC, murine APC, and purified plasma kallikrein .
Target:
Research Areas:
PPACK II diTFA is an irreversible and specific glandular and plasma kallikreins inhibitor .
Cat. No.: HY-150052
CAS No.: 1357950-47-0
Target:
Research Areas:
Plasma kallikrein-IN-3 is a plasma kallikrein inhibitor (IC50: 0.15 μM). Plasma kallikrein-IN-3 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
Cat. No.: HY-150519
CAS No.: 1551460-43-5
Target:
Research Areas:
FXIa/Plasma kallikrein-IN-1 is an inhibitor of coagulation factor XIa (FXIa) and plasma kallikrein with Ki values of 187.70 nM and 151.6 nM, respectively. FXIa/Plasma kallikrein-IN-1 can be used in the research of thromboembolic diseases .
Cat. No.: HY-143476
Target:
Research Areas:
Plasma kallikrein-IN-2 (Compound 198) is a potent plasma kallikrein (PKal) inhibitor with an IC50 of 0.1 nM. Plasma kallikrein-IN-2 can be used for hereditary angioedema, diabetic macular edema, and diabetic retinopathy research .
Cat. No.: HY-W662576
CAS No.: 1417691-95-2
Target:
Research Areas:
KVD-001 is a potent plasma kallikrein inhibitor. KVD-001 can be used for diabetic macular edema research .
Cat. No.: HY-108814
CAS No.: 460738-38-9
Synonyms: DX-88
Target:
Research Areas:
Target:
Research Areas:
LSP-249 (example 35), extracted from patent WO2016011209A1, is a plasma kallikrein inhibitor under the study for angioedema, with an EC50 less than 100 nM in cell .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
